Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain.

Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A. · 2017

Read Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. by Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5317055.txt.

Introduction

Mette Frahm Olsen and co-authors reviewed studies of pain relief in BMC Medicine in 2017. Trials need a yardstick for the smallest drop in pain that a patient can feel as real relief. That yardstick is called the minimum clinically important difference. For sudden pain, studies had set it at many unlike values, with no shared agreement.

The team gathered thirty-seven studies with more than eight thousand patients. Most set the yardstick as the mean pain drop among people who said they felt a bit better. A few set it as the cut point that best split better from not better. Values spread very wide, and the spread was too large for one pooled answer. The pain level at the start of care drove much of the gap for fixed values. The authors urge care in picking a yardstick for new trials.

Catalog record

CREATOROlsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5317055

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain By Mette Frahm Olsen, Eik Bjerre, Maria Damkjær Hansen, Jørgen Hilden, Nino Emanuel Landler, Britta Tendal, Asbjørn Hróbjartsson Published in: BMC Medicine DOI: 10.1186/s12916-016-0775-3 ABSTRACT Background The minimum clinically important difference (MCID) is used to interpret the clinical relevance of results reported by trials and meta-analyses as well as to plan sample sizes in new studies. However, there is a lack of consensus about the size of MCID in acute pain, which is a core symptom affecting patients across many clinical conditions. Methods We identified and systematically reviewed empirical studies of MCID in acute pain. We searched PubMed, EMBASE and Cochrane Library, and included prospective studies determining MCID using a patient-reported anchor and a one-dimensional pain scale (e.g. 100 mm visual analogue scale). We summarised results and explored reasons for heterogeneity applying meta-regression, subgroup analyses and individual patient data meta-analyses. Results We included 37 studies (8479 patients). Thirty-five studies used a mean change approach, i.e. MCID was assessed as the mean difference in pain score among patients who reported a minimum degree of improvement, while seven studies used a threshold approach, i.e. MCID was assessed as the threshold in pain reduction associated with the best accuracy (sensitivity and specificity) for identifying improved patients. Meta-analyses found considerable heterogeneity between studies (absolute MCID: I2 = 93%, relative MCID: I2 = 75%) and results were therefore presented qualitatively, while analyses focused on exploring reasons for heterogeneity. The reported absolute MCID values ranged widely from 8 to 40 mm (standardised to a 100 mm scale) and the relative MCID values from 13% to 85%. From analyses of individual patient data (seven studies, 918 patients), we found baseline pain strongly associated with absolute, but not relative, MCID as patients with higher baseline pain needed larger pain reduction to perceive relief. Subgroup analyses showed that the definition of improved patients (one or several categories improvement or meaningful change) and the design of studies (single or multiple measurements) also influenced MCID values. Conclusions The MCID in acute pain varied greatly between studies and was influenced by baseline pain, definitions of improved patients and study design. MCID is context-specific and potentially misguiding if determined, applied or interpreted inappropriately. Explicit and conscientious reflections on the choice of a reference value are required when using MCID to classify research results as clinically important or trivial. BACKGROUND It can be challenging to decide whether a modest effect in a randomised clinical trial, or a meta-analysis of several such trials, is clinically relevant. Statistical tests inform on the probability of a result being a chance finding; however, they convey no information on whether a given effect will be experienced as important by patients. The degree of pain reduction that is considered clinically relevant has an impact on which analgesic interventions are regarded clinically useful. This interpretation problem for clinical relevance has been at the core of debates of the importance of several types of interventions intended for reducing acute pain, for example, paracetamol [1–3], non-steroidal anti-inflammatory drugs [4, 5], morphine or synthetic opiates [6], corticosteroids [7], muscle relaxants [4], laser therapy [8], transcranial direct current stimulation [9], EMLA cream [10], and acupuncture [11]. A related challenge involves the calculation of sample sizes for clinical trials, where researchers need to know the smallest clinically important effect that the trial should not miss to be able to determine an adequate sample size. Jaeschke et al. [12] characterised the concept of minimum clinically relevant difference in 1989 as “the smallest difference in score in the domain of interest which participants perceive as beneficial and which would mandate, in the absence of troublesome side effects and costs, a change in the patient’s management”. The strength of the concept is that it defines a relevant effect size based on clinical considerations and not only statistical significance [13, 14]. It has subsequently been supplemented by a related concept – the substantial (and not only minimum) clinically relevant difference [15]. The minimum clinically important difference (MCID) is sometimes chosen on the basis of expert consensus judgement [16], statistical models [17] or objective criteria [18]. However, in acute pain, it seems reasonable to anchor clinical relevance to the patients’ experience. This approach is in accordance with the increasing awareness of the relevance of patient-reported outcomes in clinical research [19]. Several such empirical studies have been conducted to determine the MCID in acute pain, but they differ with regard to methodology, clinical condition and findings, and have not yet been systematically reviewed. Since acute pain is a core symptom in healthcare, an assessment of the MCID and a clarification of the causes for its variation will have broad interest. It has been suggested that baseline pain influences absolute values of MCID, but study reports have been conflicting [20, 21], and it remains unclear which other clinical or methodological factors are of importance. We therefore decided to systematically review empirical studies of the MCID in acute pain relief and to examine possible causes for variation between study results, especially their likely dependency on baseline pain levels. We also reviewed studies of the substantial clinically important difference in acute pain relief as well as clinically important differences for worsening of pain. METHODS Eligibility criteria We included prospective studies of patients with acute pain, regardless of age, clinical condition, and intervention, in which pain intensity was assessed on a one-dimensional scale, e.g. a 100 mm visual analogue scale (VAS) or a 0–10 point numerical rating scale (NRS), and in which the MCID was determined using an anchor-based method using patients’ perception of change to determine clinical importance. Pain was considered acute when its duration was less than 1 month or, if duration was not indicated, when it was described as such in a study report. Studies were excluded if they were not clinical (i.e. used healthy volunteers) or determined the MCID from objective criteria (e.g. return to work), the distribution of data (e.g. the minimum detectable difference) or expert consensus. A typical eligible study would ask patients to score their pain intensity, e.g. using a VAS, at baseline and follow-up. At follow-up, patients were also asked to categorise their change in pain intensity using response options such as ‘no change’, ‘a little better’/‘somewhat better’, and ‘a lot better’/‘much better’. The MCID was then determined from the change in scores on the pain scale among patients having categorised their change as ‘a little better’ (or a similar expression indicating a minimum clinically important improvement). We included studies with two types of analytical approaches (1) the ‘mean change approach’, i.e. the mean difference in pain scores among patients who reported a minimum degree of pain relief [22]; or (2) the ‘threshold approach’, i.e. the threshold value for pain score change which most accurately (yield i ng best sensitivity and specificity) identified patients experiencing relevant pain relief in analogy with a diagnostic test where the gold standard is patients’ perception of change [23]. Search strategy We searched PubMed, EMBASE and Cochrane Library until August 2016 with no language restrictions. The core search string was: (minimal OR minimally OR minimum OR ‘clinically significant’ OR ‘clinically important’ OR ‘clinically

Read the complete text